Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1-(4-(((6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl)amino)methyl)-1-piperidinyl)-2-propen-1-one
2. 2-propen-1-one, 1-(4-(((6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl)amino)methyl)-1-piperidinyl)-
1. 1415823-73-2
2. 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one
3. Evobrutinib [inn]
4. Msc2364447c
5. M-2951
6. Msc-2364447c
7. Za45457l1k
8. M2951
9. 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one
10. 1-(4-((6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino)-methyl)-piperidin-1-yl)-propenone
11. 2-propen-1-one, 1-(4-(((6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl)amino)methyl)-1-piperidinyl)-
12. 1-(4-(((6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl)amino)methyl)-1-piperidinyl)-2-propen-1-one
13. 1-[4-({[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino}methyl)piperidin-1-yl]prop-2-en-1-one
14. 1-[4-[[[6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl]amino]methyl]-1-piperidinyl]-2-propen-1-one
15. M-2951; Evobrutinib
16. Evobrutinib [who-dd]
17. Unii-za45457l1k
18. Gtpl9752
19. Chembl4072833
20. Schembl14165673
21. Bdbm291522
22. Us9580449, Example A39
23. Bcp28995
24. Ex-a2691
25. Us9580449, Example A250
26. Nsc800892
27. S8777
28. Zinc205623965
29. Ab90800
30. Cs-6303
31. Db15170
32. Nsc-800892
33. Msc 2364447
34. Ac-35533
35. Bs-15355
36. Db-126809
37. Hy-101215
38. A16824
39. D71175
40. A902526
41. A250 [wo2012170976]
42. Q27295200
43. M-2951; M 2951; M2951; Msc-2364447c; Msc 2364447c; Msc2364447c
44. N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine
| Molecular Weight | 429.5 g/mol |
|---|---|
| Molecular Formula | C25H27N5O2 |
| XLogP3 | 4.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 7 |
| Exact Mass | 429.21647512 g/mol |
| Monoisotopic Mass | 429.21647512 g/mol |
| Topological Polar Surface Area | 93.4 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 595 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of multiple sclerosis
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Evobrutinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Evobrutinib, including repackagers and relabelers. The FDA regulates Evobrutinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Evobrutinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Evobrutinib supplier is an individual or a company that provides Evobrutinib active pharmaceutical ingredient (API) or Evobrutinib finished formulations upon request. The Evobrutinib suppliers may include Evobrutinib API manufacturers, exporters, distributors and traders.
Evobrutinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Evobrutinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Evobrutinib GMP manufacturer or Evobrutinib GMP API supplier for your needs.
A Evobrutinib CoA (Certificate of Analysis) is a formal document that attests to Evobrutinib's compliance with Evobrutinib specifications and serves as a tool for batch-level quality control.
Evobrutinib CoA mostly includes findings from lab analyses of a specific batch. For each Evobrutinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Evobrutinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Evobrutinib EP), Evobrutinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Evobrutinib USP).
LOOKING FOR A SUPPLIER?
